A neutral comparison of Henry Meds and Mochi Health on advertised price, fees, and disclosures. Sorted facts, no preference, no “best overall.”
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Factor | Henry Meds | Mochi Health |
|---|---|---|
| Advertised tirzepatide | $179 flat | ~$278 eff. |
| Membership | None (stated) | ~$79/mo required |
| Bundled programming | Meds-focused | Dietitian/curriculum (stated) |
| Provenance | secondary | secondary |
On price, Henry Meds’ flat $179 is well below Mochi’s ~$278 effective, which includes a required membership and more structured programming. If you want bundled coaching you may value Mochi’s extras; if you want lowest medication cost, Henry Meds leads. Both figures are secondary and pending re-verification. Neither is FDA-approved.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.